ReviewInvestigative ophthalmology & visual science2011
Dark matters in AMD genetics: epigenetics and stochasticity.
Review in Investigative ophthalmology & visual science, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between Vascular Endothelial Growth Factor Polymorphisms and Age-Related Macular Degeneration: An Updated Meta-Analysis.Disease markers · 2016Pooled it
- Integrative Landscape of Dry AMD Pathogenesis, Models, and Emerging Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Nomogram Based on A-To-I RNA Editing for Predicting Overall Survival in Patients With Breast Cancer.Journal of cellular and molecular medicine · 2025Article
- Genetic Aspects of Age-Related Macular Degeneration and Their Therapeutic Potential.International journal of molecular sciences · 2022Review
- Potential of Long Non-Coding RNAs in Age-Related Macular Degeneration.International journal of molecular sciences · 2021Review
- Anti-VEGF Drugs Influence Epigenetic Regulation and AMD-Specific Molecular Markers in ARPE-19 Cells.Cells · 2021Article
- DICER1 in the Pathogenesis of Age-related Macular Degeneration (AMD) -Aging and disease · 2020Review
- Expression of VEGFA-regulating miRNAs and mortality in wet AMD.Journal of cellular and molecular medicine · 2019Article
- Increased expression of ApoE and protection from amyloid-beta toxicity in transmitochondrial cybrids with haplogroup K mtDNA.Neurobiology of disease · 2016Article
- Tyro3 Modulates Mertk-Associated Retinal Degeneration.PLoS genetics · 2015Article
- The role of epigenetics in age-related macular degeneration.Eye (London, England) · 2014Review
- Oxidative stress, hypoxia, and autophagy in the neovascular processes of age-related macular degeneration.BioMed research international · 2014Review
- Stem cells: a new paradigm for disease modeling and developing therapies for age-related macular degeneration.Journal of translational medicine · 2013Article
- Epigenetics and autism.Autism research and treatment · 2013Review
- Mechanism of inflammation in age-related macular degeneration: an up-to-date on genetic landmarks.Mediators of inflammation · 2013Review
- Review: Epigenetic mechanisms in ocular disease.Molecular vision · 2013Review
- Dry age-related macular degeneration: A currently unmet clinical need.Intractable & rare diseases research · 2012Review
- Mechanism of inflammation in age-related macular degeneration.Mediators of inflammation · 2012Review
- The Role of Mitochondria in AMD: Current Knowledge and Future Applications.Journal of ophthalmic & vision researchArticle
- Genetic and Epigenetic Regulation in Age-related Macular Degeneration.Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.